Term	Definition
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SC	Steering Committee
SR	Significant Risk
SID	Subject Identification
SNM	Sacral Neuromodulation
TNM	Tibial Neuromodulation
UF	Urinary Frequency
UI	Urinary Incontinence
UPS	Urgency Perception Scale
USADE	Unanticipated Serious Adverse Device Effect
UU	Urinary Urgency
UUI	Urge Urinary Incontinence
WPAI:SHP	Work Productivity and Activity Impairment Questionnaire: Specific Health Problem

3 Synopsis

Title	**ENDURANCE: Post Approval Effectiveness aNd DURAbility EvaluatioN of the Altaviva Tibial DeviCE**
Clinical Study Type	Post-Market Study
Product Name	Altaviva™ system
Sponsor Name and Address	Medtronic Pelvic Health 7000 Central Ave NE Minneapolis, MN 55432 USA

Indication under investigation	The indication under investigation is for the treatment of urge urinary incontinence (UUI) in patients who failed or could not tolerate more conservative treatments.
Investigation Purpose	The primary purpose of this prospective, multicenter study is to assess the long-term safety and effectiveness of the Altaviva™ system for the treatment of UUI.
Objective(s)	<u>Primary Effectiveness Objective:</u> - To evaluate the UUI responder rate annually through 60 months after implant. A UUI responder is defined as having at least 50% improvement from baseline in daily UUI episodes. <u>Additional Objectives:</u> - To evaluate the following measures annually through 60 months: o Change from baseline in daily UUI episodes o UUI responder rate for subjects age 65 and older o Change in OAB-q HRQL o Other urinary symptoms as measured with voiding diaries ▪ Change from baseline in daily UF episodes in subjects with UF at baseline ▪ Change in daily urgent episodes ▪ Change in urinary urgency based on the IUSS ▪ Complete continence rate ▪ Change in nocturia rate

	o Change in urinary urgency as measured with the Urgency Perception Scale (UPS) o Change in general mental health as measured with GHQ-12 overall total score (for 6-month, 12-month and 60-month visits only) o Change in sexual matters quality of life as measured with ICIQ-FLUTSsex or ICIQ-MLUTSsex overall total score (for 6-month, 12-month and 60-month visits only) o Change in work productivity and activity impairment as measured with the WPAI:SHP (for 6-month, 12-month and 60-month visits only) o Patient reported impression of improvement as measured with the Patient Global Impression of Improvement (PGI-I) questionnaire o Patient satisfaction o Physician/site staff satisfaction (for implant and 12-month visits only) o To evaluate device and system usage data <u>Safety Objectives:</u> - To evaluate procedure-, device-, and/or therapy-related adverse events through 60 months by reporting the number of events, and number and percentage of subjects with events - To evaluate serious adverse events through 60 months by reporting the number of events, and number and percentage of subjects with events
Primary Endpoint	The primary endpoint is the UUI responder rate, which is defined as the proportion of subjects experiencing at least 50% improvement in daily UUI compared to

	baseline. The UUI responder rate will be measured annually through 60 months.
Study Design	This is a prospective, multicenter, single-arm, open-label study to assess the long-term safety and effectiveness of Altaviva™ system for treatment of UUI. Subjects that have symptoms of UUI will be enrolled. The study is intended to be conducted at approximately 30 institutions in the United States. Eligible subjects will sign a study-specific informed consent form (ICF). Subjects will complete an Enrollment/Baseline Visit, a Device Implant Visit, 1-month, 6-month, 12-month and annual follow-up visits thereafter until the 60-month follow-up visit is complete.
Inclusion/Exclusion Criteria	Inclusion Criteria: • Candidate for Altaviva™ therapy per Altaviva™ labeling • Have a diagnosis of UUI as demonstrated on a 3-day voiding diary by having a minimum of 3 episodes of urinary urge incontinence in 72 hours • If taking OAB medications, subjects should be on a stable dose for at least 3 months prior to baseline and willing to remain on stable treatment through completion of the 12-month voiding diary • Patient must be willing and able to accurately complete study questionnaires, attend visits, operate the system, and comply with the study protocol • Willing and able to provide signed and dated informed consent Exclusion Criteria:

	• Patient who is not a candidate for Altaviva™ therapy per Altaviva™ labeling, including: ○ Patients who are considered to be poor surgical candidates or who are at risk for poor wound healing per Altaviva™ labeling ○ Have progressive, systemic neurological disease ○ Have clinically significant peripheral neuropathy in the lower leg ○ Severe, uncontrolled diabetes • Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component based on physician judgment • Current symptomatic urinary tract infection • Patients will be excluded if they have been treated with percutaneous tibial nerve stimulation (PTNS)/percutaneous tibial neuromodulation (PTNM) therapy in the past 4 weeks, or longer if the investigator judges that the therapeutic effect is still present • Patients who have had treatment of urinary symptoms with botulinum toxin therapy or sacral neuromodulation in the past 6 months • History of a prior implantable tibial neuromodulation system • Patients who are pregnant or planning to become pregnant during the course of the study • Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound study results
Study Procedures and Assessments	This is an observational study intended to collect data consistent with routine clinical care practices. **Study Visits**

	• Enrollment/Baseline Visit • Device Implant Visit • 1-month Follow-up Visit • 6-month Follow-up Visit • 12-month Follow-up Visit • 24-month Follow-up Visit • 36-month Follow-up Visit • 48-month Follow-up Visit • 60-month Follow up Visit **Enrollment/Baseline Visit:** • Demographics • Medical history and medications • Voiding diary • OAB-q • UPS • GHQ-12 • ICIQ-FLUTSsex or ICIQ-MLUTSsex • WPAI:SHP Adverse events **Device Implant Visit:** • Procedure information • Motor/sensory thresholds • An ultrasound of the tibial nerve may be completed • Physician/site staff satisfaction questionnaire may be completed • Programming/device data • Adverse events and/or device deficiencies **1-, 6-, 12-, 24-, 36-, 48-, and 60-Month Follow-up Visits:** • Motor/sensory thresholds • An ultrasound of the tibial nerve may be completed • Voiding diary

	• OAB-q • UPS • PGI-I • 6, 12 and 60 Months only: GHQ-12 • 6, 12 and 60 Months only: ICIQ-FLUTSsex or ICIQ-MLUTSsex • 6, 12 and 60 Months only: WPAI:SHP • Patient satisfaction • Physician/site staff satisfaction questionnaire may be completed at 12 Months only • Programming/device data • Adverse events and/or device deficiencies **System Modification** • Procedure information • Motor/sensory thresholds • An ultrasound of the tibial nerve may be completed • Voiding diary (if applicable) • Programming/device data • Adverse events and/or device deficiencies Safety-reported events will be collected on an ongoing basis during the subject's participation in the study. All adverse events (including serious and related adverse events) and device deficiencies will be collected.
Data Collection	Longer term follow-up frequency is intended to align with anticipated routine clinical care practices to obtain real-world data collection. In addition to study required visits, additional visits for routine care practices are allowed and may vary for several reasons including but not limited to: physician preference, a patient's condition and/or personal circumstances.